PharmaJet Announces Clinical Results from Scancell’s COVID-19 DNA Vaccine Study Exclusively Administered with Needle-free Precision Delivery Systems
PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, today announced that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1 COVIDITY clinical trial. The trial was conducted at the University of Cape Town Lung Institute in South Africa to assess the safety and immunogenicity of their COVID-19 DNA candidate vaccines, SCOV1 and SCOV2. The vaccines were exclusively administered using the PharmaJet Tropis® and Stratis® needle-free precision delivery systems.
The results from the trial were highly encouraging, inducing neutralizing antibody and T cell responses with no safety concerns. Administration with PharmaJet’s devices was well received by study participants. This new set of human data adds to the growing evidence indicating that this modern needle-free administration technology is an increasingly viable option to enhance plasmid DNA vaccine immune response.
Professor Lindy Durrant, Chief Executive Officer, Scancell, commented, “We are encouraged by these results. The trial validates that AvidiMab®-modified immunotherapies boost immune responses and PharmaJet’s Needle-free Injection Systems are effective in delivering our ImmunoBody®-generated drug candidate. Our plans are to include PharmaJet Needle-free precision delivery systems in future trials with our immuno-oncology projects.’’
Chris Cappello, President and CEO, PharmaJet, said, “We are pleased by our collaboration with Scancell and we look forward to potentially contributing more as an advanced administration partner. Our precision delivery systems have demonstrated improved immune response for multiple DNA and RNA vaccines1 and our intradermal administration platform played a critical role in the commercialization of the world’s first plasmid DNA vaccine2. We operate at industrial scale, and we are able to rapidly deploy our systems for all stages of a clinical program as well as for the commercialization of vaccines developed in combination with our injection systems.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more